Ara
Toplam kayıt 7, listelenen: 1-7
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)
(BMC, 2023)
Following publication of the original article [1], the authors reported an error in the author name of Enes Erul.
Effects of chitosan nanoparticles with long synthetic siRNAs targeting VEGF in triple-negative breast cancer cells
(Faculdade de Ciencias Farmaceuticas (Biblioteca), 2023)
Vascular endothelial growth factor (VEGF) is an essential angiogenic factor in breast cancer development and metastasis. Small interfering RNAs (siRNAs) can specifically silence genes via the RNA interference pathway, ...
Dosimetric comparison of 3-dimensional conformal technique, intensity-modulated, volumetric arc modulation, and helical tomotherapy with radixact in patients with breast cancer
(Kare Publishing, 2023)
OBJECTIVE Adjuvant radiotherapy (RT) has been used often at breast cancer treatment. RT techniques differ from each other in terms of accessibility and applicability. We aimed to compare the dosimetric evaluations of four ...
Intra-operative partial breast irradiation versus external whole breast irradiation for early breast cancer
(NLM (Medline), 2023)
Aims: Intra-operative radiotherapy (IORT) is a new alternative way to give radiation therapy. During surgery to remove breast cancer, radiation is given as a single dose directly to the area where the tumor used to be. The ...
The correlation between progesterone and mammographic density in postmenopausal women: A systematic review of the literature and meta-analysis
(Cureus Inc, 2023)
Higher mammographic breast density in premenopausal and postmenopausal women is related to a higher breast cancer risk. In this review, we analyze the correlation between estrogen, progesterone, and mammographic density ...
Quantitative measurement of HER2/neu oncogene amplification and p53 tumor suppressor gene deletion by RT-PCR in breast cancer
(Istanbul University Press, 2023)
Objective: The aim of the study was to quantitatively evaluate HER2/neu oncogene amplification and p53 tumor suppressor gene deletion in breast cancer with real-time polymerase chain reaction (RT-PCR). Materials and Methods: ...
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study
(Taylor & Francis Ltd, 2023)
AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) ...